Defence Announces Dr. Maxime Parisotto as CSO, Director of Science and Business Development
Defence Therapeutics has appointed Dr. Maxime Parisotto as Chief Scientific Officer, Director of Science and Business Development. Dr. Parisotto brings over 20 years of experience in biochemistry, drug development, and innovation, holding a PhD focused on breast cancer and metabolism. His background includes postdoctoral fellowships at IGBMC and Universit茅 de Montr茅al, and a senior analyst role at adMare Bioinnovations. He will complete his MBA from Sherbrooke University in April 2025. The company has granted him 100,000 incentive stock options, exercisable at 60 cents per share for three years. The announcement also notes that Dr. Moutih Rafei has left the company.
Defence Therapeutics ha nominato il Dott. Maxime Parisotto come Chief Scientific Officer e Direttore della Scienza e dello Sviluppo Commerciale. Il Dott. Parisotto porta con s茅 oltre 20 anni di esperienza in biochimica, sviluppo di farmaci e innovazione, avendo conseguito un dottorato di ricerca incentrato sul cancro al seno e sul metabolismo. La sua carriera include incarichi post-dottorali presso l'IGBMC e l'Universit茅 de Montr茅al, nonch茅 un ruolo di analista senior presso adMare Bioinnovations. Completando il suo MBA presso l'Universit脿 di Sherbrooke nell'aprile del 2025. L'azienda gli ha assegnato 100.000 opzioni stock incentive, esercitabili a 60 centesimi per azione per tre anni. L'annuncio precisa anche che il Dott. Moutih Rafei ha lasciato l'azienda.
Defence Therapeutics ha nombrado al Dr. Maxime Parisotto como Director Cient铆fico y Director de Ciencia y Desarrollo Empresarial. El Dr. Parisotto aporta m谩s de 20 a帽os de experiencia en bioqu铆mica, desarrollo de medicamentos e innovaci贸n, con un doctorado centrado en el c谩ncer de mama y el metabolismo. Su experiencia incluye becas postdoctorales en el IGBMC y la Universit茅 de Montr茅al, as铆 como un papel de analista senior en adMare Bioinnovations. Completar脿 su MBA en la Universidad de Sherbrooke en abril de 2025. La empresa le ha otorgado 100,000 opciones de acciones como incentivo, que se pueden ejercer a 60 centavos por acci贸n durante tres a帽os. El anuncio tambi茅n indica que el Dr. Moutih Rafei ha dejado la empresa.
Defence Therapeutics電� Maxime Parisotto 氚曥偓毳� 斓滉碃 瓿柬暀 毂呾瀯鞛愳澊鞛� 瓿柬暀 氚� 牍勳雼堨姢 臧滊皽 鞚挫偓搿� 鞛勲獏頄堨姷雼堧嫟. Parisotto 氚曥偓電� 20雲� 鞚挫儊鞚� 靸濏檾頃�, 鞎诫 臧滊皽 氚� 順侅嫚 瓴巾棙鞚� 氤挫湢頃橁碃 鞛堨溂氅�, 鞙犽癌鞎� 氚� 雽�靷棎 欷戩爯鞚� 霊� 氚曥偓 頃欖渼毳� 臧�歆�瓿� 鞛堨姷雼堧嫟. 攴胳潣 瓴诫牓鞐愲姅 IGBMC 氚� 氇姼毽槵 雽�頃欖棎靹滌潣 氚曥偓頉� 鞐瓣惮鞗� 瓴诫牓鞚� 鞛堨溂氅�, adMare Bioinnovations鞐愳劀 靹犾瀯 攵勳劃臧�搿� 頇滊彊頄堨姷雼堧嫟. 攴鸽姅 2025雲� 4鞗� 靺旊笇耄� 雽�頃欔祼鞐愳劀 MBA毳� 毵堨範 鞓堨爼鞛呺媹雼�. 須岇偓電� 攴胳棎瓴� 100,000臧滌潣 鞙犾澑 鞀ろ啞 鞓奠厴鞚� 攵�鞐晿鞓�鞙茧┌, 鞚措姅 欤茧嫻 60靹柬姼搿� 3雲勱皠 頄夓偓頃� 靾� 鞛堨姷雼堧嫟. 鞚� 氚滍憸鞐愳劀電� Moutih Rafei 氚曥偓臧� 須岇偓毳� 霒犽偓雼る姅 雮挫毄霃� 鞏戈笁頃橁碃 鞛堨姷雼堧嫟.
Defence Therapeutics a nomm茅 le Dr Maxime Parisotto au poste de directeur scientifique et directeur de la science et du d茅veloppement commercial. Le Dr Parisotto apporte plus de 20 ans d'exp茅rience en biochimie, d茅veloppement de m茅dicaments et innovation, avec un doctorat ax茅 sur le cancer du sein et le m茅tabolisme. Son parcours inclut des bourses postdoctorales 脿 l'IGBMC et 脿 l'Universit茅 de Montr茅al, ainsi qu'un r么le d'analyste senior chez adMare Bioinnovations. Il compl茅tera son MBA 脿 l'Universit茅 de Sherbrooke en avril 2025. L'entreprise lui a accord茅 100 000 options d'achat d'actions incitatives, exer莽ables 脿 60 cents par action pendant trois ans. L'annonce pr茅cise 茅galement que le Dr Moutih Rafei a quitt茅 l'entreprise.
Defence Therapeutics hat Dr. Maxime Parisotto zum Chief Scientific Officer und Direktor f眉r Wissenschaft und Gesch盲ftsentwicklung ernannt. Dr. Parisotto bringt 眉ber 20 Jahre Erfahrung in Biochemie, Arzneimittelentwicklung und Innovation mit und hat einen Doktortitel, der sich auf Brustkrebs und Stoffwechsel konzentriert. Zu seinem Werdegang geh枚ren Postdoc-Stellen am IGBMC und an der Universit茅 de Montr茅al sowie eine Position als leitender Analyst bei adMare Bioinnovations. Er wird sein MBA-Studium an der Universit盲t Sherbrooke im April 2025 abschlie脽en. Das Unternehmen hat ihm 100.000 Anreiz-Aktienoptionen gew盲hrt, die f眉r drei Jahre zu 60 Cent pro Aktie ausge眉bt werden k枚nnen. In der Mitteilung wird auch erw盲hnt, dass Dr. Moutih Rafei das Unternehmen verlassen hat.
- Appointment of experienced CSO with 20+ years in drug development and innovation
- New CSO brings dual expertise in scientific research and business development
- Extensive professional network in biotech ecosystem
- Departure of previous scientific leadership (Dr. Moutih Rafei)
- Stock option grant of 100,000 shares may cause minor dilution
Vancouver, British Columbia--(Newsfile Corp. - November 25, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company developing radiopharmaceuticals and ADC products using its proprietary platform and drug delivery technologies in addition to novel immune-oncology vaccines, is pleased to announce that Dr. Maxime Parisotto has joined the Company as Chief Scientific Officer, Director of Science and Business Development.
Dr. Maxime Parisotto is a seasoned biochemist with over 20 years of experience spanning academic research, drug development, and innovation. He holds a PhD in biochemistry focused on breast cancer and metabolism and has held postdoctoral fellowships at prestigious institutions, including the IGBMC in Strasbourg, France, and the Université de Montréal. As Senior Analyst, he contributed to significant investment decisions at adMare Bioinnovations. He also holds a graduate certificate in life science entrepreneurship development from Concordia university and will be graduating with an MBA from Sherbrooke University in April 2025.
Dr. Parisotto has a robust track record of leadership, including managing multidisciplinary teams, contributing to high-impact scientific publications. Before joining adMare, he led research initiatives in cancer biology and stem cells at institutions such as the IRCM and Université de Montréal. He is an active member of the Canadian biotech ecosystem, with an extensive professional network contacts and regular participation in national and international conferences. His research and business interests focus on advancing drug development from discovery to clinical stages and fostering collaborations between academia, industry, and investors to drive innovation in biopharmaceuticals. His scientific expertise's are mainly in oncology, protein biochemistry, cell metabolism and stem cells biology.
"I am honored and excited to join Defence Therapeutics as CSO, Director of Science & Business Development. I strongly believe that Defence's proprietary Accum® technology platform has a great potential for the development of targeted therapies that will make a difference for the patients," mentioned Dr. Maxime Parisotto.
"We are proud to welcome Dr. Maxime Parisotto as he is an accomplished and strong scientist with a mission to focus on the scientific programs that will increase the value of Defence Therapeutics. His business knowledge is definitely an important aspect that will guide and inspire the Company's growth and development for the benefit of Defence's shareholders," mentioned Sébastien Plouffe, President, CEO and Founder of Defence Therapeutics.
The Company has granted 100,000 incentive stock options to Dr. Parisotto, in accordance with the terms and conditions of Defence's stock option plan. Each stock option vests immediately and is exercisable at a price of 60 cents per share for a period of three years from the grant date.
Defence would like to mention that Dr. Moutih Rafei is no longer with the Company. The Company would like to thank Dr. Rafei for his contributions.
About Defence:
Defence Therapeutics is a publicly-traded clinical-stage biotechnology company developing and engineering the next generation of radio-immuno-conjugate and ADC products using its proprietary platform in addition to novel immune-oncology vaccines. The core of Defence Therapeutics platform is the ACCUM® technology, which enables precision delivery of radio-immuno-conjugates or ADCs in their intact form to target cells, and vaccine antigens. As a result, increased efficacy and potency can be reached against catastrophic illness such as cancer and infectious diseases.
For further information:
Sebastien Plouffe, President, CEO and Director
P: (514) 947-2272
Splouffe@defencetherapeutics.com
Cautionary Statement Regarding "Forward-Looking" Information
Neither the CSE nor its market regulator, as that term is defined in the policies of the CSE, accepts responsibility for the adequacy or accuracy of this release.
To view the source version of this press release, please visit
FAQ
Who is the new CSO of Defence Therapeutics (DTCFF)?
What are Dr. Parisotto's qualifications at Defence Therapeutics (DTCFF)?
What stock options were granted to the new CSO of Defence Therapeutics (DTCFF)?
